US Stock Market Move | "Cooperation clarification" once caused a sharp decline, with Mangoceuticals (MGRX.US) stock prices riding a roller coaster.

On Friday, the remote medical platform Mangoceuticals (MGRX.US) fell by about 13% in pre-market trading, but recovered to a slight increase of 2.94% after opening, closing at $1.225. The company had previously denied any cooperation with Eli Lilly (LLY.US) and Novo Nordisk A/S Sponsored ADR Class B (NVO.US), overturning a statement made the day before. On Thursday before market opening, Mangoceuticals claimed to have reached a cooperation agreement with Eli Lilly and Novo Nordisk A/S Sponsored ADR Class B to provide users with the weight loss drugs of the two pharmaceutical giants through the MangoRx Direct and PeachesRx Direct projects. However, the situation suddenly reversed, as Eli Lilly publicly denied any cooperation and Novo Nordisk A/S Sponsored ADR Class B did not confirm the collaboration.